Canadian Agency for Drugs and Technologies in Health. (2016). CADTH Canadian Drug Expert Committee final recommendation: Indication: asthma. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.). Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Final Recommendation: Indication: Asthma. Omalizumab -- Resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Final Recommendation: Indication: Asthma. Omalizumab -- Resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.). Canadian Agency for Drugs and Technologies in Health, 2016.
